SCHEMBL15212136

SCHEMBL15212136

CCCCN(CCCC)CCC(N)OC(N)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTR1A P08908 1/20 0.37
GAA P10253 1/20 0.37
CYP2D6 P10635 1/20 0.37
DRD3 P35462 1/20 0.37
SCN1A P35498 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
CA1 P00915 3/20 0.36
CA12 O43570 2/20 0.36
CA9 Q16790 2/20 0.36
CA2 P00918 1/20 0.35
KDM5A P29375 3/20 0.35
PHF8 Q9UPP1 2/20 0.33
PLA2G1B P04054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16290200 0.81 CA2 (0.47) CHRM2LMNACA1CA2SLC1A2
SCHEMBL27413544 0.78 GRIK1 (0.49) SLC1A2SLC1A1GRIK1GRIK2TP53
SCHEMBL27703023 0.77
SCHEMBL15212192 0.76 CHRNB2 (0.37) CHRM2LMNACHRM4CHRM5CHRM1
SCHEMBL15456105 0.73 MMP1 (0.36) CA1CA12CA9CA2SLC1A2
SCHEMBL28166380 0.73 KDM5A (0.47) CHRM2LMNACYP1A2CYP3A4HTR1A
Carbamic Acid SCHEMBL28649191 0.72 KDM5A (0.50) CHRM2LMNACYP1A2CYP3A4HTR1A
Acetone SCHEMBL27904025 0.72 CA12 (0.54) CHRM2LMNACYP1A2CYP3A4HTR1A
SCHEMBL8399766 0.71 FAAH (0.41) CHRM2LMNACYP1A2CYP3A4HTR1A
SCHEMBL9407962 0.71 PLA2G1B (0.41) CHRM2LMNACYP1A2CYP3A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015184326-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC. (US) 2015-12-03 WO disclosed
WO-2015057847-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC. (US) 2015-04-23 WO disclosed
EP-2817345-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS Cerulean Pharma Inc. (US) 2014-12-31 EP disclosed
US-20140037573-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC (US) 2014-02-06 US disclosed
WO-2013126564-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS CERULEAN PHARMA INC. (US) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140037573-A1 CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS SYNCRIP, EXOSC5, EXOSC9 CHRM2 4830/4885LMNA 267/4885CYP1A2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.